HPV vaccine controversies

Marta del Pino

Consultor Unidad Ginecología Oncológica. Hospital Clínico de Barcelona Institut de d'Investigacions Biomèdiques August Pi Sunyer Profesor asociado Universidad de Barcelona




HPV vaccine challenging questions

Marta del Pino

Consultor Unidad Ginecología Oncológica. Hospital Clínico de Barcelona Institut de d'Investigacions Biomèdiques August Pi Sunyer Profesor asociado Universidad de Barcelona




HPV vaccine development




Firsts studies...

Study	Design	Study group	Control	n	Inclusion	Participants
FUTURE I		4v (3 dosis)	Placebo	5 455 ♀ (16–24 a)	January 2002- Match 2003	16 countries
FUTURE II	Phase III controlled randomized, double blinded, (1:1)	4v (3 dosis)	Placebo	12 167	June 2002- May 2003	13 countries
PATRICIA		2v (3 dosis)	Hepatitis A	18 644♀ (15–25 a)	May 2004- June 2005	14 countries
Costa Rica HPV-16/18 Vaccine Trial (Guanacaste Study)	Study communitarian, controlled randomized, double blinded, (1:1)	2v (3 dosis)	Hepatitis A	7 466 ♀ (18–25 a)	June 2004- December 2005	Costa Rica




HPV vaccine and cervical cancer reduction




Conclusions: Since HPV vaccine introduction, both SCC and AC incidence rates declined among women aged 15–20 years, a group not typically screened for cervical cancer, which may suggest HPV vaccine impact.





Vaccinated at \leq 16





Falcaro M et al. The lancet 2021 Mix JM et al. Cancer Epidemiol Biomarkers Prev 2021 Palmer TJ et al. JNCI 2024 Arbyn M at el. JNCI 2024

But... what happens in adults?

And what happens beyond the cervix?

Immunogenicity

HPV vaccine in adults: immunogenicity

n = 3253 women aged 27-45 years (FUTURE III study) + 150 men aged 27–45 years (MAM study)

	Women ageo	d 27–45 years (Group A)	Women age	d 16–26 years (Group B)	Group A	'Group B
Assay (cLIA)	n	GMT (mMU/mL)	n	GMT (mMU/mL)	GMT ratio	95% Cl
Anti-HPV 6	1083	412.4	2800	536.2	0.77	0.72; 0.82
Anti-HPV 11	1083	538.2	2824	754.3	0.71	0.67; 0.76
Anti-HPV 16	1092	2212.0	2749	2297.6	0.96	0.89; 1.0
Anti-HPV 18	1223	348.4	3006	458.1	0.76	0.71; 0.82
	Men aged	27–45 years (Group C)	Men aged	16–26 years (Group D)	Group C/	Group D
Assay (cLIA)	n	GMT (mMU/mL)	n	GMT (mMU/mL)	GMT ratio	95% Cl
Anti-HPV 6	115	364.9	1092	447.6	0.82	0.65; 1.03
Anti-HPV 11	136	489.9	1092	624.0	0.79	0.66; 0.93
Anti-HPV 16	111	2177.8	1135	2404.3	0.91	0.72; 1.1
Anti-HPV 18	135	296.2	1174	402.3	0.74	0.59; 0.9

HPV vaccine in men who have sex with men (MSM)

in MSW		SIM ed HM (N = 1,726) GMT (mMU/m <7 473.9 81.6 73.4 <8 651.5		$\frac{\text{GMT (mMU ml)}}{\text{GMT (mMU ml)}}$ <7 274.3 64.6 49.2 <8 (21.2)	Anti-HPV 6 Anti-HPV 11 Anti-HPV 16 Anti-HPV 18 Anti-HPV 31 Anti-HPV 33 Anti-HPV 45 Anti-HPV 52 Anti-HPV 58	GMT Ratio 0.81 0.77 0.82 0.89 0.74 0.78 0.85 0.70 0.78	95% Cl (0.70, 0.93) (0.67, 0.89) (0.72, 0.94) (0.77, 1.04) (0.64, 0.86) (0.69, 0.89) (0.72, 0.99) (0.61, 0.80) (0.68, 0.89)	MSM/♀
4 6	n 978 978 851 792	GMT (mMU/m <7 473.9 81.6 73.4	nl) n 114 114 90 55	GMT (mMU ml) <7 274.3 64.6 49.2	Anti-HPV 11 Anti-HPV 16 Anti-HPV 18 Anti-HPV 31 Anti-HPV 33 Anti-HPV 45 Anti-HPV 52	0.77 0.82 0.89 0.74 0.78 0.85 0.70	(0.67, 0.89) (0.72, 0.94) (0.77, 1.04) (0.64, 0.86) (0.69, 0.89) (0.72, 0.99) (0.61, 0.80)	MSM/♀
4 6	n 978 978 851 792	GMT (mMU/m <7 473.9 81.6 73.4	nl) n 114 114 90 55	GMT (mMU ml) <7 274.3 64.6 49.2	Anti-HPV 16 Anti-HPV 18 Anti-HPV 31 Anti-HPV 33 Anti-HPV 45 Anti-HPV 52	0.82 0.89 0.74 0.78 0.85 0.70	(0.72, 0.94) (0.77, 1.04) (0.64, 0.86) (0.69, 0.89) (0.72, 0.99) (0.61, 0.80)	MSM/♀
4 6	978 851 792	473.9 81.6 73.4	114 90 55	274.3 64.6 49.2	Anti-HPV 33 Anti-HPV 45 Anti-HPV 52	0.78 0.85 0.70	(0.69, 0.89) (0.72, 0.99) (0.61, 0.80)	I
					Anti-HPV 52	0.70	(0.61, 0.80)	
	070	(515	114	(2) 2				
ody	res	sponse	e was	numerica and wor	lly lower ir nen	n MSM t	than in H	IM
4	1,032 1,032 897	<10 439.3 39.4	142 142 114	<10 212.1 31.4	Anti-HPV 18 Anti-HPV 31 Anti-HPV 33 Anti-HPV 45	0.75 0.59 0.66 0.67	(0.64, 0.88) (0.51, 0.69) (0.57, 0.75) (0.57, 0.79)	MSM/d
		1,032	1,032 439.3 897 39.4	1,032 439.3 142 897 39.4 114	1,032 <10 142 <10 1,032 439.3 142 212.1 897 39.4 114 31.4	1,032 <10 142 <10 Anti-HPV 18 1,032 439.3 142 212.1 Anti-HPV 33 897 39.4 114 31.4 Anti-HPV 45 836 33.9 69 24.7 Anti-HPV 52	Anti-HPV 18 0.75 1,032 <10	Anti-HPV 18 0.75 (0.64, 0.88) 1,032 <10

GMTs Comparison in MSM vs. women/MSW (7-m)

9v HPV vaccine

4v HPV vaccine

Immunogenicity in MSM

HPV vaccine in people living with HIV

Immunogenicity in PLHIV

Review: 43 studies

4v HPV vaccine. Seropositivity 28 weeks post-3rd doses

- HPV 16: 0.99 (95% CI: 0.98-1.00, n=9)
- HPV 18: 0.94 (95% CI: 0.91-0.96, n=9)
- HPV 6: 0.99 (95% CI: 0.97-1.00, n=8)
- HPV 11: 0.98 (95% CI: 0.97-0.99, n=8)

9v HPV vaccine. Seropositivity 28 weeks post-3rd doses

- HPV 16: 1.00 (95% CI: 0.98-1.00)
- HPV 18: 1.00 (95% CI: 0.99-1.00)

High rate of seroconversion for all HPV vaccine types

2v HPV vaccine. Seropositivity 28 weeks post-3rd doses

- HPV 16: 0.99 (95% CI: 0.95-1.00)
- HPV 18: 0.99 (95% CI: 0.96-1.00)



HPV vaccine in people living with HIV

Implications of all the available evidence

PLHIV can develop a robust humoral immune response following HPV vaccination. The vaccine is safe and well tolerated, with few serious adverse events. Evidence of vaccine efficacy on biological outcomes following vaccination was generally of low quality. The evidence-base is lacking from well-designed studies that account for the underlying HPV infection status, timing of infection, and have a sample size and follow-up time that are appropriate for estimation of efficacy of HPV vaccine in PLHIV. The evidence of a robust immune response generated among all PLHIV who have received HPV vaccination supports cervical cancer elimination efforts to increase HPV vaccination coverage including in high HIV prevalence settings.

Efficacy/Effectiveness

HPV vaccine efficacy/effectiveness in the cervix (women)

n = 3253 women aged 50 yea	ars (LTFU FUTURE III study)		Person- Years	Incidence per 10,000 Person-Years	
		m/n	Follow-up	Cases (95% Cl)	m/n
	HPV6/11/16/18-related CIN or condyloma Per-protocol population ^b				
	Base study	0/528	1794.2	0.0 (0.0–20.6)	13/528
	LTFU study	0/529	2946.7	0.0 (0.0–12.5)	
	ITP population ^c				
	Base study	1/587	2308.8	4.3 (0.1–24.1)	17/573
	LTFU study	0/586	3263.0	0.0 (0.0–11.3)	0/557
	HPV16/18-related CIN2 or worse				
	Per-protocol population ^b				
	Base study	0/513	1694.2	0.0 (0.0–21.8)	3/518
	LTFU study	0/482	2679.0	0.0 (0.0–13.8)	_
	ITP population ^c				
	Base study	1/578	2192.8	4.6 (0.1–25.4)	4/564
	LTFU study	0/535	2976.8	0.0 (0.0–12.4)	0/511
	HPV6/11-related condyloma				
	Per-protocol population ^b				
	Base study	0/443	1505.7	0.0 (0.0–24.5)	2/428
1 1	LTFU study	0/443	2460.4	0.0 (0.0–15.0)	
	ITP population ^c				
	Base study	0/491	1937.3	0.0 (0.0–19.0)	4/468
	LTFU study	0/491	2724.6	0.0 (0.0–13.5)	0/465

There were no cases of high-grade cervical dysplasia or genital warts caused by HPV vaccine types up to 10 years post-dose 3 in women vaccinated (4v) up to 50 years

HPV vaccine efficacy/effectiveness in the anus (adult)

Vaccine Efficacy/Effectiveness (VE) against vaccine-targeted anal HPV infection (14 studies)


Outcome	No. of Studies [References]	No. of Participants	VE (95% CI), %	
Incident/prevalent anal HF	PV infection			
Age ≤26 y].
PPE in clinical trials	2 [16, 17]	2390	84 (77–90)	6 studies (2 clinical trials and 4 real-world studies) in
ITT in clinical trials	2 [16, 17]	4885	55 (39–67)	
Real-world studies	4 [18–21]	2735	77 (40–91)	individuals (98% HIV-negative) ≤26 y
Age >26 y				
ITT in clinical trials	1 [22]	100	14 (–19 to 38)	1 clinical trial in men having sex with men living with HIV >2
Persistent anal HPV infec	tion ^b			
Age ≤26 y				
PPE in clinical trials	2 [17, 23]	1345	98 (87–100)	2 clinical trials that recruited HIV-negative men 16–26 y
ITT in clinical trials	1 [17]	551	59 (43–71)	
Age >26 y				
PPE in clinical trials	1 [24]	554	31 (–82 to 74)	1 aligned trial in popula living with LUV (> 26 yr
ITT in clinical trials	1 [24]	574	35 (–5 to 60)	1 clinical trial in people living with HIV >26 y

HPV vaccine efficacy/effectiveness in the anus (adults)

Vaccine Efficacy/Effectiveness (VE) against anal intraepithelial neoplasia and anal condyloma (14 studies)

Outcome	No. of Studies [References]	No. of Participants	5 VE (95% CI)	
AIN1+				
Age ≤26 y				
PPE in clinical trials ^a	2 [17, 25]	668	82 (39–94)	2 clinical trial in individuals (men having sex with men ; 81% HIV negative) ≤26 y
ITT in clinical trials ^a	1 [17]	551	50 (26-67)	1 clinical trial in individuals (men having sex with men ; HIV negative) ≤26 y
Age >26 y				
ITT in clinical trials ^a	1 [24]	262	17 (–6 to 35)	1 clinical trials in individuals (82% men having sex with men 18% women; all
AIN2+				living with HIV) >26 y
Age ≤26 y				
PPE in clinical trials ^a	1 [17]	402	75 (14–93)	1 clinical trial in individuals (men having sex with men ; HIV negative) ≤26 y
ITT in clinical trials ^a	1 [17]	551	54 (21–73)	
Age >26 y				2 clinical trials in individuals (85% men having sex with men 15% women; all
ITT in clinical trials ^a	2 [22, 24]	702	-1 (-42 to 28)	living with HIV) >26 y
Anal condyloma				
Age ≤26 y				
PPE in clinical trials ^a	1 [17]	402	100 (8–100)	1 clinical trial in individuals (men having sex with men HIV negative) \leq 26 y
ITT in clinical trials ^a	1 [17]	551	57 (16–80)	
Age >26 y				
Real-world studies ^b	1 [26]	313	55 (8–78)	1 real world study in individuals (men having sex with men HIV negative) >26 y Wei F et al L, et al. JID. 2023

HPV vaccine efficacy/effectiveness anal HSIL (women)





Vaccination status	Unadjusted HR (95% CI)	Adjusted [®] HR (95% CI)	
Unvaccinated	Referent	Referent	
Age at vaccination younger than 17 y	0.30 (0.10 to 0.89)	0.30 (0.10 to 0.87)	
Age at vaccination 17-32 y	1.30 (0.78 to 2.15)	1.21 (0.73 to 2.03)	

HSIL: high-grade squamous intraepithelial lesion

HPV vaccine efficacy/effectiveness in anogenital HSIL (men)

936 participants (827 heterosexual men and 109 MSM up to 26 years). Long term follow-up study (10 years)

	Early vacci	nation group (n	=936)	Catch-up v	accination group	(n=867)	reduction estimate (95% CI)*
	Participants	Person-years follow-up	Incidence per 10 000 person-years (95% CI)	Participants	Person-years follow-up	Incidence per 10 000 person-years (95% CI)	
External genital warts related to H	PV6 or 11						
Per-protocol population							
Base study	2/640	1518.9	13.2 (1.6–47.6)	20/623	1456.5	137.3 (83.9–212.1)	90·4% (62·3 to 98·4)
Long-term follow-up study	0/639	4225·4	0.0 (0.0-8.7)				
mITT population							
Base study	6/763	2203.9	27.2 (10.0–59.3)	31/725	2072.2	149.6 (101.6–212.3)	81·8% (55·9 to 92·6)
Long-term follow-up study	0/763	5054.1	0.0 (0.0–7.3)	0/567	2737.2	0.0 (0.0–13.5)	
External genital lesions† related to	HPV6, 11, 16, or 18						
Per-protocol population							
Base study	2/731	1728.4	11.6 (1.4–41.8)	23/704	1638.1	140.4 (89.0–210.7)	91·8% (69·4 to 98·6)
Long-term follow-up study	0/730	4798.4	0.0 (0.0–7.7)				
mITT population							

The HPV vaccine provides durable protection against anogenital disease related to HPV6, 11, 16, and 18.

HPV vaccine and disease in people living with HIV

Reference	N (age)	Study	Results
Women			
McClymont et al. 2019	279 (9-25a)	observational, cohorts prospective	Lower incidence of persistent infection (but higher rate of HPV vaccine failure.
Firnhaber et al. 2021	180 (35-45a)	randomized double-blinded clinical trial	Post treatment CIN2+ was similar between the vaccine and placebo arms BUT 73% showed positive margins for HSIL
MSM & Women			
Wilkin et al. 2018	575 (>27a)	randomized double-blinded clinical trial	No efficacy for prevention of anal HPV infection and disease. Stop studio BUT high level of current and prior HPV infection
MSM			
Hidalgo-Tenorio et al. 2021	129 (>26a)	randomized double-blinded clinical trial	No efficacy for prevention of anal disease BUT 74% showed prevalent high-risk HPV and 60% low-risk HPV infection
Palefsky et al. 2021	144 (18-26a)	phase II, open-label, multicenter trial	No incident qHPV type-associated anal lesions among men naive to that type
Gosens et al. 2021	126 (> 18a)	randomized, double-blind, multicentre trial	No efficacy for prevention of anal recurrence posttreatment BUT no HPV testing after treatment

HPV vaccine and guidelines for people living with HIV

	CDC/ACIP	EACS 2022	BHIVA 2015	WHO
Recommended age	11 or 12 (9–26)	9-45	12-13	9-14
Age limit for catch- up	26 (to 45 with shared decision making)	45	26 (to 40 for women and MSM)	Not specified
Number of doses	3	3	3	3 (preferred). Alternative 2-dose regimen >6-month interval
Preferred HPV vaccine	9vHPV (only vaccine currently distributed in US)	9vHPV	9vHPV	2vHPV, 4vHPV or 9vHPV
CD4 and VL at time of vaccination	No specific recommendation	Preferably when CD4>200 and suppressed VL	ART-naïve patients with CD4<200, vaccine may be deferred until ART establishment	No specific recommendation

CDC, Centers for Disease Control and Prevention; ACIP, Advisory Committee on Immunization Practices; EACS, European AIDS Clinical Society; BHIVA, British HIV association; WHO, World Health Organization


Efficacy/Effectiveness in recurrence

HPV vaccine and previous HPV/SIL history

	Study	Vaccinated	Unvaccinated		Effectiveness (%)	Weight (%)
PAVIVE Study (sistematic review):	(author, year)	F/S	F/S		[95% CI]	
ATTE Olday (Sistematic review).	Post-excision			:		
	Kang (2013) ³⁵	9/351	27/350		64.8 (25.1 to 83.5)	7.39
20 studies (2011-2023)	Gómez de la Rosa (2021) ⁴⁸	4/156	16/155		71.9 (14.5 to 90.8)	5.62
	Karimi-Zarchi (2020) ⁴⁵	12/31	20/14		72.9 (29.6 to 89.6)	6.36
	Petrillo (2020) ⁴⁶	6/176	14/89	——————————————————————————————————————	78.3 (41.7 to 91.9)	6.19
	Del Pino (2020) ⁴⁴	5/148	12/100		79.6 (30.5 to 94.0)	5.13
	Karimi-Zarchi (2020) ⁴⁵	11/39	21/14	∎	81.2 (51.3 to 92.7)	6.38

The present meta-analysis and meta-regression showed that conisation supported by three-dose vaccination against HPV can reduce the recurrence of CIN2+ in women by more than 69%

compared with excisional treatment only.





Re-activation and HPV-related disease

High quality evidence is coming....

1. NOVEL trial – UK (Finland, Sweden) <u>Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial - Full Text View -</u> <u>ClinicalTrials.gov</u>

2. HOPE9 trial - Italy


Impact on Disease Relapse of HPV Vaccination in Women Treated With LEEP for Cervical Intraepithelial Neoplasia. HOPE9 -Full Text View - ClinicalTrials.gov

3. VACCIN study - Netherlands

Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial - PubMed (nih.gov)

4. COVENANT trial - South Africa, HIV + women

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV - Full Text View -ClinicalTrials.gov



HPV vaccine and previous HPV/SIL history


Related to HPV status after the treatment

		Clinical Outcome at the End of Follow-Up					
Status at the First Control (6	Post-Conization Months)	No Disease	Persistent/Recurrent LSIL/HPV	Persistent/Recurren HSIL	t p*		
No	disease ($n = 153$)				0.032		
Non-vao	ccinated	55 (83.3)	7 (10.7)	4 (6.1)			
Vacci	nated	78 (89.7)	9 (10.3)	0 (0.0)			
Persiste	nt LSIL/HPV ($n = 1$	101)			0.173		
Non-vao	ccinated	28 (65.1)	9 (20.9)	6 (14.0)			
Vacci	nated	33 (56.9)	21 (36.2)	4 (6.9)			
Persister	nt HSIL/CIN2-3 (<i>n</i> =	= 11)			0.131		
Non-vao	ccinated	0 (0.0)	1 (33.3)	2 (66.7)			
Vacci	nated	3 (37.5)	4 (50.0)	1 (12.5)			

del Pino M. Vaccines 2020 Rykkelid M et al. Pathogens 2024

HPV vaccine and previous HPV/SIL history

HPV vaccination after exposure. Mechanism of action: Prophylactic HPV vaccine elicit production of antibodies that bind to L1 at the surface of viral particles, hindering their ability to infect host cells



Vaccination may prevent new HPV infections caused by a different HPV type or re-infections with the same HPV type coming from a new exposure (i.e. infected partner) or through autoinoculation from an adjacent infected site

Reuschenbach M et al. Vaccines 2023 Schiffman M, et al.. Nat Rev Dis Primers 2016 Schiller JT, et al. Gynecologic oncology 2010

Autoinoculation and HPV-related disease

Sequential HPV acquisition between anal and genital sites (n=2022 women)

Risk of anal infection

% 100 ₁ <u>−</u> _{Women}


In conclusion, men and women with previous HPV infection at the genital or anal site had a higher risk for sequentially acquiring a concordant HPV infection at the other site. For anogenital HPV infection, autoinoculation of HPV might play a major role, in addition to that of sexual intercourse, espe-



Wei F et al. Emerg Infect Dis. www.cdc.gov/eid 2020

HPV vaccine and vulva disease recurrence reduction

Woman with vulvar precancer or prior genital warts




HPV vaccine and anal disease recurrence reduction over 17y

Vaccine Efficacy/Effectiveness (VE) against anal intraepithelial lesion recurrence (4 studies)

Vaccine Group, No.		Nonvaccine Group, No.				Moight %	
Event	Total	Event	Total		VE (95% CI), %	weight, %	_
							-
12	88	35	114		48 (–1 to 73)	31.9	HIV positive
27	43	27	47	F	–9 (–53 to 22)	53.2	
44	64	38	62	<u>ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا ا </u>	–3 (–234 to 68)	14.8	
				⊢ ♦ 1	14 (-41 to 48)	100.0	maan aga 27 50 v
P = .15							mean age 37–50 y
loma							
6	40	19	62		51 (–13 to 79)]	
	Event 12 27 44 P = .15 Ioma	Event Total 12 88 27 43 44 64 P = .15 Ioma	Event Total Event 12 88 35 27 43 27 44 64 38 P = .15 Ioma Ioma	Event Total Event Total 12 88 35 114 27 43 27 47 44 64 38 62 P = .15 Ioma Ioma Ioma Ioma	Event Total Event Total 12 88 35 114 27 43 27 47 44 64 38 62 $P = .15$ 6 40 19 62	Event Total Event Total VE (95% Cl), % 12 88 35 114 48 (-1 to 73) 27 43 27 47 -9 (-53 to 22) 44 64 38 62 -3 (-234 to 68) Idea $P = .15$ Idea	Event Total Event Total VE (95% CI), % Weight, % 12 88 35 114

Conclusions: Watch out with the confounding factors



Thanks for your attention